A significant legislative push is underway to consolidate federal oversight of the dietary supplement industry, aiming to dismantle a growing patchwork of state-specific regulations. Proposed by Representative Nick Langworthy, R-N.Y., the Dietary Supplement Regulatory Uniformity Act, introduced on February 4, 2026, seeks to reaffirm the U.S. Food and Drug Administration’s (FDA) authority nationwide, a move proponents argue will restore common sense and clarity to the sector.
The impetus for this federal intervention appears to stem from a perceived overreach by individual states, creating a fragmented and often contradictory regulatory landscape for businesses operating across state lines and for consumers seeking consistent product information. This legislative initiative highlights a broader debate about federal versus state authority in regulating consumer products, particularly those with evolving scientific understanding and significant market presence.
The Proliferation of State-Level Regulations: A Growing Concern
The current legislative effort is a direct response to a trend that has seen numerous states enact their own laws governing dietary supplements, often diverging from federal guidelines or addressing specific product categories with unique state-level mandates. This phenomenon gained significant momentum in the wake of the 2018 Farm Bill, which legalized hemp and, by extension, opened the door for the widespread availability of cannabidiol (CBD) products.
Despite explicit directives from Congress urging the FDA to establish a federal regulatory framework for CBD, the agency’s prolonged inaction led many state lawmakers to step in. This resulted in a complex web of state-specific regulations for CBD, creating a challenging environment for manufacturers and retailers. Estimates suggest that by late 2025, over 30 states had introduced or enacted legislation specifically targeting CBD products, ranging from labeling requirements and testing mandates to outright sales bans in certain contexts. This regulatory uncertainty not only hindered market growth but also raised concerns about consumer safety and product consistency.
A similar pattern has emerged concerning weight-loss and muscle-building supplements, with several states proposing or enacting laws to restrict their sale to minors. Proponents of these state-level measures often cite concerns that these products can exacerbate eating disorders among young people. While the intention may be to protect vulnerable populations, critics argue that such state-specific prohibitions create significant compliance burdens for businesses and confuse consumers. New York, for instance, has already implemented such a law, which remains in effect despite ongoing legal challenges, underscoring the real-world impact of these diverging state approaches.
The introduction of the Dietary Supplement Regulatory Uniformity Act suggests a recognition at the federal level that this state-by-state regulatory fragmentation is unsustainable and potentially detrimental to both industry innovation and consumer protection. Representative Langworthy’s office has been vocal about the issue, with statements indicating that “New York is notorious for baseless overregulation that burdens small businesses without making anyone safer or improving public health. When states ignore science and override FDA determinations, consumers are misled and local businesses pay the price.” This sentiment reflects a broader frustration within the industry that state-level actions are often driven by public perception or limited scientific interpretation rather than comprehensive federal oversight.
The Scientific Debate: Supplements and Eating Disorders
A central tenet of some state-level legislation, particularly those restricting sales to minors, is the purported link between certain dietary supplements and the exacerbation of eating disorders. This notion is largely attributed to the work of the Strategic Training Initiative for the Prevention of Eating Disorders (STRIPED), an initiative associated with the T. H. Chan School of Public Health at Harvard University, led by S. Bryn Austin, Ph.D.
However, this perspective does not command universal support within the broader nutritional research community. Many experts maintain that the scientific evidence establishing a direct causal link between dietary supplements and the development or exacerbation of eating disorders remains inconclusive. A comprehensive review published in the journal Nutrients in 2023 by nutritional scientist Susan Hewlings, Ph.D., concluded, "The evidence to date does not support a causative role for dietary supplements in eating disorders." Dr. Hewlings further emphasized, "Public health policy and resources should be focused on scientifically established approaches to reduce the prevalence of eating disorders."
This scientific disagreement forms a critical part of the debate surrounding the Dietary Supplement Regulatory Uniformity Act. Proponents of federal preemption argue that regulatory actions should be based on robust scientific consensus, which they contend is lacking in the case of a direct link between these supplements and eating disorders. They assert that state laws based on more limited or contested research can lead to unwarranted restrictions that penalize responsible businesses and products.
The proposed federal bill aims to address these disparities by establishing a unified, science-based national standard. Representative Langworthy has articulated this vision, stating, "At its core, this bill is about protecting consumer health and common sense. If a product is safe under federal law, it shouldn’t be treated as dangerous in New York and lawful just across the border. We can safeguard public health without crushing small businesses, and that’s exactly what this legislation does.” This perspective underscores the goal of creating a predictable regulatory environment where product safety and efficacy are assessed consistently across the nation.
Industry Unites Behind Federal Preemption
The introduction of the Dietary Supplement Regulatory Uniformity Act has garnered significant support from major trade organizations within the dietary supplement industry. The Consumer Healthcare Products Association (CHPA), Natural Products Association (NPA), American Herbal Products Association (AHPA), and the Council for Responsible Nutrition (CRN) have all issued joint statements endorsing the legislation.
This unified front reflects a shared concern over the disruptive impact of inconsistent state regulations. Scott Melville, President and CEO of CHPA, highlighted the importance of a national standard, stating, "This legislation secures a single, science-based national standard for dietary supplements, providing the clarity, consistency and consumer confidence Americans deserve.” This sentiment is echoed by Steve Mister, President and CEO of CRN, who added, "This legislation protects consumers from confusing and alarmist state-level restrictions and requirements while ensuring responsible companies can continue to innovate and provide safe, high-quality products nationwide.”
Daniel Fabricant, Ph.D., CEO of NPA, characterized the bill as "a decisive and long-overdue answer to state overreach, which has become a defining threat to consumers and the future of the dietary supplement industry." Graham Rigby, President and CEO of AHPA, emphasized the economic implications, noting that "An inconsistent patchwork of state regulations would create a highly restrictive environment that would stifle innovation, increase business compliance costs and complexity, and ultimately restrict consumer access."
The industry’s collective endorsement suggests that the current state-led regulatory approach is viewed as a significant impediment to growth, innovation, and consumer access. The call for federal preemption is rooted in the belief that a single, federally enforced standard, aligned with existing frameworks like the Dietary Supplement Health and Education Act (DSHEA), is the most effective way to ensure both consumer safety and a thriving marketplace. This unified industry stance is likely to amplify the legislative push for the Dietary Supplement Regulatory Uniformity Act.
Broader Implications and the Path Forward
The proposed Dietary Supplement Regulatory Uniformity Act has the potential to reshape the regulatory landscape for dietary supplements in the United States. By reasserting federal authority, the bill aims to bring predictability and uniformity to a sector that has been increasingly challenged by a fragmented state-by-state regulatory environment.
The implications of this legislation are far-reaching. For businesses, it promises to reduce compliance costs and administrative burdens associated with navigating diverse state laws, potentially fostering greater investment and innovation. For consumers, it aims to ensure a consistent level of product safety and information across the nation, reducing confusion and enhancing trust.
However, the legislative process is often complex, and the passage of the Dietary Supplement Regulatory Uniformity Act is not guaranteed. It will likely face scrutiny and debate, particularly from proponents of state-level control who may argue that their measures are necessary to address specific public health concerns that they believe are not adequately handled by federal oversight. The scientific debate surrounding the link between supplements and eating disorders will undoubtedly continue to be a focal point.
The bill’s success will likely depend on its ability to garner bipartisan support and effectively address concerns about consumer protection without stifling legitimate business operations. The FDA’s role in this evolving regulatory environment will also be critical. While the proposed act aims to clarify federal authority, the agency’s ongoing actions and interpretations of existing laws, such as its approach to defining and regulating ingredients under DSHEA, will continue to shape the industry.
As the legislative process unfolds, stakeholders will be closely watching the progress of the Dietary Supplement Regulatory Uniformity Act, recognizing its potential to significantly influence the future of the dietary supplement market in the United States. The outcome of this legislative effort will ultimately determine whether the nation moves towards a more cohesive and federally driven approach to supplement regulation, or if the current patchwork of state laws continues to evolve.